238 related articles for article (PubMed ID: 26742713)
1. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
3. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of
Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
[TBL] [Abstract][Full Text] [Related]
5. PET Imaging of VLA-4 in a New BRAF
Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
7. First-in-Humans Evaluation of Safety and Dosimetry of
Laforest R; Ghai A; Fraum TJ; Oyama R; Frye J; Kaemmerer H; Gaehle G; Voller T; Mpoy C; Rogers BE; Fiala M; Shoghi KI; Achilefu S; Rettig M; Vij R; DiPersio JF; Schwarz S; Shokeen M; Dehdashti F
J Nucl Med; 2023 Feb; 64(2):320-328. PubMed ID: 36008121
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
9. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Al
Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
[TBL] [Abstract][Full Text] [Related]
11. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Beaino W; Nedrow JR; Anderson CJ
Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
[TBL] [Abstract][Full Text] [Related]
15. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
16. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
18. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
[TBL] [Abstract][Full Text] [Related]
20. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [
Ghai A; Fettig N; Fontana F; DiPersio J; Rettig M; Neal JO; Achilefu S; Shoghi KI; Shokeen M
EJNMMI Res; 2021 Sep; 11(1):97. PubMed ID: 34586539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
